Across TCGA pan-cancer cohorts, C11orf54 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C11orf54 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher C11orf54 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C11orf54 expression acts as an unfavorable survival marker.
ACC are the cancer types where C11orf54 Mutation most reproducibly stratifies survival.